HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide

NCT07760948 on ClinicalTrials.gov · last registry update 2026-08-28

Registered but not yet open, with 90 participants planned. Due to report 30 November 2029, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Change in Appendicular Lean Mass. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Vanderbilt University Medical Center
Sponsor type: Other
Enrollment: 90
Started: 2026-12-01
Primary completion: 2029-11-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Appendicular Lean Mass

Conditions studied

Type 2 Diabetes Mellitus (T2DM) · Sarcopenia · Obesity · Muscle Loss · Older Adults

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.